The PDGFR pathway is overactivated and inhibition with imatinib, a small molecule inhibitor targeting multiple tyrosine kinases, in the IMPRES trial resulted in improved exercise capacity and hemodynamics in PAH patients, but serious adverse events were common [4]. Here, PDGFRB is linked to pulmonary arterial hypertension.